

WYDUR Board Meeting Minutes
Thursday, July 19, 2007
Laramie, Wyoming
11 a.m. – 3 p.m.

Members present: Steve Brown, Mike Carpenter, Becky Drnas, Bill Harrison, Kurt Hopfensperger, Richard Johnson, Scott Johnston, Bill Keenan, Kevin Robinett, Dean Wunsch

Ex-officio: Roxanne Homar, Donna Artery, Antoinette Brown, James Bush, Linda Martin

Guests: Adam Sosa (Ortho-McNeil Janssen), Kelley Digby (Johnson and Johnson), Glen Patchener (Pfizer), Micahael Schultz (Forest Labs), Joe Busby (Lilly), John Stockton (Genentech), Terry Ahlers (Pfizer), Gary Mueller (Pfizer), J. Bush (WDOH), Betty Iverson (Wyeth), Joe Hansen (Forest), Jeff Jenkins (Merck), Chris Peryam (UW Pharmacy School student), Garrett Povlos (UW Pharmacy School student), Matt Titchener (UW Pharmacy School student), Nick Schofield (UW Pharmacy School student), Kerri Powell (WDOH intern), Melissa Hunter (UW Pharmacy School faculty).

Dr. Harrison called the meeting to order at 11:01 a.m.

Introductions were made.

Minutes of May 2007

The minutes of the May 31, 2007 meeting were approved as presented.

Department of Health

Antoinette gave an update on the regulation requiring the use of tamper resistant prescription pads effective October 1, 2007 for all Medicaid prescriptions. The Office of Pharmacy Services will write to Wyoming's Congressional delegation regarding their concerns. The intent of the bill was to require tamper resistant prescription pads for narcotics only, which is currently required in Wyoming. The Department will monitor the situation on the national level.

Old Business

The Department continues to work with Dr. Robinett on preferred drugs and criteria for the antidepressants. The topic was tabled for discussion at the September meeting.

Dr. Johnston gave an overview of the literature review he conducted on paliperidone. This review is available upon request. A representative from Janssen outlined the differences between risperidone and paliperidone, especially the differences in metabolic pathways and the availability of paliperidone in the OROS release system. The Board recommended that the Department require prior authorization for paliperidone claims for greater than 6 mg daily dosing, recipients under age 18 and for diagnoses other

than schizophrenia, bipolar disorder and psychotic disorders. The Department will draft proposed criteria for Board approval and release for public comment in September.

New Business

Lyrica's new indication for fibromyalgia was discussed. A thorough review of fibromyalgia was provided by the Department of Health pharmacy intern, Kerri Powell. After much discussion, it was determined that educational approaches regarding the disease and treatment guidelines should be investigated. At the next meeting, treatment guidelines, Medicaid-specific statistics and educational opportunities will be provided for discussion of future steps. The Board recommended approval of Lyrica for fibromyalgia.

Open comments

No open comments were presented.

The Board met in closed session for planning purposes. The following revised mission statement and goals were approved:

Mission

The mission of the Wyoming Drug Utilization Review Board is to enhance quality of patient care by assuring appropriate drug therapy, optimal patient outcomes, and education for health care providers.

Goals:

Goal 1:

Criteria and standards developed by WYDUR shall be clinically relevant and derived through evaluation of peer-reviewed literature, compendia, guidelines obtained from professional groups, health care providers, data and experience obtained by WYDUR.

Goal 2:

Criteria and standards developed by WYDUR shall be non-proprietary and shall be developed and revised through a consensus process. The criteria and standards development and revision process shall consider timely public comment before adoption.

Goal 3:

The costs of drug therapy shall be considered after clinical and patient considerations are addressed.

Goal 4:

WYDUR shall provide consistent education to providers and the public.

There being no further business, the meeting adjourned at 3:00 p.m.

Respectfully submitted,

Aimee Lewis
WYDUR Manager